A study on the mechanisms underlying resistance acquisition of lung cancer for tyrosine kinase inhibitors
| Project/Area Number |
21590384
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Kitasato University |
|---|
Principal Investigator |
JIANG Shi-xu 北里大学, 医学部, 講師 (70276153)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 肺癌 / EGFR / Met / 分子標的抗腫瘍薬 / 薬剤耐性 / MET |
|---|
| Research Abstract |
Tyrosine kinase inhibitor(TKI) is effective for lung cancers with EGFR mutation, but these tumors eventually acquire drug resistance. In the present study, we found that some TKI-treated tumors mainly composed of EGFR-wild tumor dells while the EGFR-mutant ones vanished or markedly decreased, and their pre-treated tumors contained EGFR-wild tumor cells. Furthermore, with surgically resected TKI-untreated cases, we showed that most EGFR-mutant tumors also contained EGFR-wild tumor cells. Thus, multiple mechanisms underline acquired TKI resistance, and besides the reported secondary EGFR T790M mutation and adaptive Met amplification, the selective survival of the preexisting TKI-resistant EGFR-wild tumor cells also contributes to the drug acquisition.
|
Report
(4 results)
Research Products
(21 results)
-
[Journal Article] Anti-HuC and-HuD autoantibodies are differential ero-diagnostic markers for small cell carcinoma from large cell neuroendocrine carcinoma of the lung2012
Author(s)
Matsumoto T, Rygue S Kobayashi M, Kageyama T, Hattori M, Goshima N, Jiang SX, Saegusa M, Iyoda A, Satoh Y, Masuda N, Sato Y
-
Journal Title
Int J Oncol
Volume: Vol.40
Pages: 1957-1962
Related Report
Peer Reviewed
-
-
[Journal Article] HADHA is a Potential Predictor of Response to Platinum-based Chemotherapy for Lung Cancer.2011
Author(s)
Kageyama T, Nagashio, R, Ryuge S, Matsumoto T, Iyoda A, Satoh Y, Masuda N, Jiang SX, Saegusa M, Sato Y
-
Journal Title
Asian Pacific J Cancer Prev
Volume: Vol.12
Pages: 3457-3463
Related Report
Peer Reviewed
-
[Journal Article] The balance between the expressions of hASH1 and HES1 differs between large cell neuroendocrine carcinoma and small cell carcinoma of the lung2011
Author(s)
Nagashio R, Sato Y, Matsumoto T, Kageyama T, Hattori M, Iyoda A, Satoh Y, Ryuge S, Masuda N, Jiang SX, Saegusa M
-
Journal Title
Lung Cancer
Volume: Vol.74, No.3
Pages: 405-410
Related Report
Peer Reviewed
-
-
-
-
-
-
[Journal Article] Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas2010
Author(s)
Nagashio R, Sato Y, Matsumoto T, Kageyama T, Satoh Y, Shinichiro Ryuge S, Masuda N, Goshima N, Jiang SX, Okayasu I
-
Journal Title
Lung Cancer
Volume: Vol.69, No.1
Pages: 54-59
Related Report
Peer Reviewed
-
[Journal Article] Significant high expression of cytokeratins 7, 8, 18, 19 in pulmonary large cell neuroendocrine carcinomas, compared to small cell lung carcinomas2010
Author(s)
Nagashio R, Sato Y, Matsumoto T, Kageyama T, Satoh Y, Ryuge S, Masuda N, Jiang SX, Okayasu I
-
Journal Title
Pathol Int
Volume: Vol.60
Pages: 71-77
Related Report
Peer Reviewed
-
[Journal Article] Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease2010
Author(s)
Fukui T, Otani S, Hataishi R, Jiang SX, Nishii Y, Igawa S, Mitsufuji H, Kubota M, Katagiri M, Masuda N
-
Journal Title
Cancer Chemother Pharmacol
Volume: Vol.65, No.4
Pages: 803-806
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
